Selected Drugs Clear All
MultiCheck Results
- 0
Interaction
Additional Considerations |
||
|
blinatumomab
in Blincyto
|
||
|
caution advised with narrow therapeutic index drugs, especially during Days 1-9 of first blinatumomab cycle and Days 1-2 of second cycle; blinatumomab may transiently increase cytokine release leading to suppression of metabolic enzymes, causing incr. drug levels and risk of adverse effects |
||